The objective of the regulatory affairs stakeholder meeting was to review the current developments, strategies and key players involved the strengthening of regulatory capacity in Africa, to ensure synergy and maximise leverage for joint funding. These include the WHO activities supported by the Gates Foundation; and the African Medicines Regulatory Harmonization (AMRH) initiative implemented through the regional economic communities and countries, spearheaded by the NEPAD Agency). It also aims to address emerging issues that directly impact on EDCTP core activities, such as clinical trial sponsorship, regulatory reviews, and the role of NRAs in pre and post registration safety monitoring of adverse events in clinical trials; and identify priority regulatory areas that may be supported in EDCTP2.
Participants at the regulatory meeting will include representatives from key organisations involved in regulatory strengthening activities in Africa and Europe. This includes WHO, NEPAD Agency, representatives from African and European regulatory agencies, European Medicines Agency, Gates Foundation, PDPs and academic institutions involved in sponsoring clinical trials.
Expected outcomes of the meeting
A report with recommendations to shape the EDCTP strategic and operational business plan was published.
Background reading material